The effects of Sacubitril/Valsartan and Amlodipine on ventricular remodeling in hypertensive patients with left ventricular hypertrophy: a prospective, randomized controlled clinical study

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2000039291

Enrollment

Unknown

Registered

2020-10-22

Start date

2020-10-09

Completion date

Unknown

Last updated

2021-01-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hpertension

Interventions

Group 1:Sacubitril/Valsartan

Group 2:Amlodipine

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1. Male or female patients aged >= 18 and = 115g / m2, female >= 95g / m2; 4. The subjects who have the ability to understand the research requirements and provide informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients with severe renal impairment (EGFR = 3 times the upper limit of normal); 3. Patients with serious cardiovascular and cerebrovascular diseases; 4. Patients with known history of angioedema related to ACEI or ARB treatment; 5. Patients with hereditary or idiopathic angioedema; 6. Subjects who were pregnant or planned to be pregnant in the course of the study.

Design outcomes

Primary

Measure	Time frame
Left Ventricular Mass Index;	—

Secondary

Measure	Time frame
mean systolic blood pressure;mean diastolic blood pressure;	—

Countries

China

Contacts

Public ContactWei Qin

Zhongda Hospital Affiliated to Southeast University

weiqin1102@163.com+86 15195986821

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026